EXPERIENCE OF THE ADALIMUMAB APPLICATION FOR THE PATIENT WITH EARLY DEBUT OF JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS
https://doi.org/10.15690/vsp.v13i4.1102
Abstract
The case of early debut and heavy course of juvenile idiopathic arthritis in the patient at the age of 1 year and 8 months, associated with uveitis refractory to the therapy by methotrexate and nonsteroid antiinflammatory preparations is presented. The given clinical example shows high therapeutic efficiency of the adalimumab. To the 8th week of treatment inflammatory changes in conjunctiva were stopped, to the 12th week the stage of inactive illness was registered, i.e. the patient had no inflammatory changes in joints, uveitis activity signs, increase of laboratory indicators of illness activity. Duration of remission of articulate syndrome and uveitis made 9 months.
Supporting agencies: Roche, Pfizer, Bristol-Myers Squibb, Centocor, Novartis.
About the Authors
K. B. Isaeva
Scientific Centre of Children Health, Moscow
Россия
Россия
E. I. Alexeeva
Scientific Centre of Children Health, Moscow;
I.M. Sechenov First Moscow State Medical University
Россия
Россия
Alexeeva Ekaterina Iosifovna, PhD, professor, Head of the Pediatric Faculty of I. M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH
R. V. Denisova
Scientific Centre of Children Health, Moscow
Россия
Россия
T. V. Sleptsova
Scientific Centre of Children Health, Moscow
Россия
Россия
Т. М. Bzarova
Scientific Centre of Children Health, Moscow
Россия
Россия
S. I. Valieva
Scientific Centre of Children Health, Moscow
Россия
Россия
E. V. Mitenko
Scientific Centre of Children Health, Moscow
Россия
Россия
E. G. Chistyakova
Scientific Centre of Children Health, Moscow;
I.M. Sechenov First Moscow State Medical University
Россия
Россия
А. М. Chomakhidze
Scientific Centre of Children Health, Moscow
Россия
Россия
References
1. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.
2. Cassidy J. T., Petty R. E. Textbook of pediatric rheumatology, 6th edn. WB Saunders Company, Philadelphia. 2011. P. 249–261.
3. Petty R. E., Southwood T. R., Manners P., Baum J., Glass D. N., Goldenberg J., He X., Maldonado-Cocco J., Orozco-Alcala J., Prieur A. M., Suarez-Almazor M. E., Woo P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004; 31: 390–392.
4. Stoll M. L., Cron R. Q. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr. Rheumatol. Online J. 2014; 12–13. Doi: 10.1186/1546-0096-12-13.
5. Lovell D. J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., Nemcova D., Mouy R., Sandborg C., Bohnsack J., Elewaut D., Foeldvari I., Gerloni V., Rovensky J., Minden K., Vehe R. K., Weiner L. W., Horneff G., Huppertz H. I., Olson N. Y., Medich J. R., Carcereri-De-Prati R., McIlraith M. J., Giannini E. H., Martini A. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008; 359: 810–820.
6. Lovell D. J., Ruperto N., Reiff A., Jung L. K., Higgins G., KonePaut I. Long-termefficacy and safety of adalimumab for up to 6 years in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2011; 63 (Suppl. 10): 265.
7. Burgos-Vargas R., Tse S. M., Horneff G., Pangan A. L., Unnebrink K., Anderson J. K. Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis. Arthritis Rheumatol. 2014; 66 (Suppl. 11): 4. Doi: 10.1002/art.38414.
8. Imagawa T., Takei S., Umebayashi H., Yamaguchi K., Itoh Y., Kawai T., Iwata N., Murata T., Okafuji I., Miyoshi M., Onoe Y., Kawano Y., Kinjo N., Mori M., Mozaffarian N., Kupper H., Santra S., Patel G., Kawai S., Yokota S. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin. Rheumatol. 2012; 31: 1713–1721.
9. Alexeeva E. I., Bzarova T. M., Valieva S. I., Denisova R. V., Isaeva K. B., Chomakhidze A. M., Chistyakova E. G., Sleptsova T. V., Mitenko E. V., Taibulatov N. I. Vopr. sovr. pediatrii — Current pediatrics. 2012; 11 (4): 82–88.
10. Kingsbury D. J., Bader-Meunier B., Patel G., Arora V., Kalabic J., Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin. Rheumatol. 2014; Doi: 10.1007/ s10067-014-2498-1.
11. Baranov A. A., Alexeeva E. I., Bzarova T. M., Valieva S. I., Denisova R. V., Isaeva K. B., Karagulyan N. A., Litvitskii P. F., Mitenko E. V., Sleptsova T. V., Fetisova A. N., Chistyakova E. G., Taibulatov N. I., Morev S. Yu. Vopr. sovr. pediatrii — Current pediatrics. 2013; 12 (1): 37–56.
12. Bzarova T. M., Alexeeva E. I., Peterkova V. A. Vopr. sovr. pediatrii — Current pediatrics. 2006; 5 (5): 13–18.
13. Ramanan A. V., Dick A. D., Benton D., Compeyrot-Lacassagne S., Dawoud D., Hardwick B., Hickey H., Hughes D., Jones A., Woo P., Edelsten C., Beresford M. W. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014; 15: 14. Doi: 10.1186/1745-6215-15-14.
Review
For citations:
Isaeva K.B., Alexeeva E.I., Denisova R.V., Sleptsova T.V., Bzarova Т.М., Valieva S.I., Mitenko E.V., Chistyakova E.G., Chomakhidze А.М. EXPERIENCE OF THE ADALIMUMAB APPLICATION FOR THE PATIENT WITH EARLY DEBUT OF JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS. Current Pediatrics. 2014;13(4):156-161. (In Russ.) https://doi.org/10.15690/vsp.v13i4.1102
Views:
1057
JATS XML
Email this article 
